Alzheimer's disease: current and future therapeutic perspectives.
1. A better understanding of the pathophysiology of AD has been made possible through population-based epidemiological studies, human genetic and post-mortem studies, leading to a number of testable hypothesis towards delaying progression. 2. A number of disease milestones have been identified as therapeutic targets, such as conversion from MCI to diagnosable dementia. 3. Clinicians caring for patients with AD have currently available a number of symptomatic drugs, and will have in the future the ability to predict the risk for asymptomatic individuals to develop AD, and provide advice towards prevention.
Gauthier
S
S
McGill Centre for Studies in Aging, Montreal, Canada.
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D018678:Cholinergic Agents / Q000494:pharmacology; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003071:Cognition; D018450:Disease Progression; D006801:Humans
D018678:Cholinergic Agents; D002800:Cholinesterase Inhibitors